OncoMatch/Clinical Trials/NCT06809530
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Is NCT06809530 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including QL1706 (bispecific antibody targeting PD-1 and CLTA-4) and Pemetrexed (Alimta) for leptomeningeal metastasis.
Treatment: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) · Pemetrexed (Alimta) — This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Cerebrospinal fluid cytopathology is positive
Prior therapy
Cannot have received: anti-PD-1 therapy
Exception: previous anti-PD1 therapy-induced pneumonitis, or ongoing >Grade 2 adverse events of such therapy
previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy
Lab requirements
Blood counts
wbc≥4000/mm3, plt≥100000/mm3
Kidney function
normal kidney function
Liver function
normal liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify